# Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Study · id `cardio:ct-nct01485614` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01485614](<https://clinicaltrials.gov/study/NCT01485614>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01485614

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT01485614. Randomized; double masking; primary purpose treatment. Start 2012-02-10 (actual); primary completion 2019-10-09 (actual). Results posted on 2020-12-16.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT01485614, source copy `cardio:ctgov-nct01485614-2022-09-23`, retrieved 2026-10-26)
- Started: 2012-02-10 (actual) (ClinicalTrials.gov record NCT01485614, source copy `cardio:ctgov-nct01485614-2022-09-23`, retrieved 2026-10-26)
- Primary completion: 2019-10-09 (actual) (ClinicalTrials.gov record NCT01485614, source copy `cardio:ctgov-nct01485614-2022-09-23`, retrieved 2026-10-26)
- Completion: 2019-10-09 (actual) (ClinicalTrials.gov record NCT01485614, source copy `cardio:ctgov-nct01485614-2022-09-23`, retrieved 2026-10-26)
- Results first posted: 2020-12-16 (ClinicalTrials.gov record NCT01485614, source copy `cardio:ctgov-nct01485614-2022-09-23`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01485614-2022-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
- Condition: Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo to sitagliptin
- Intervention (Drug): Placebo to metformin
- Intervention (Drug): Glycemic Rescue 1
- Intervention (Biological): Glycemic Rescue 2
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes (`cardio:pubmed-34779087`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e0a002dfbb36d80128e3518fb11d74146e3373bf27a8dc671d9152e794ca4b3e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
